The trajectory of companies tied to the drug's past presents a complex investment scenario . While the initial boom generated substantial returns , generic copies have significantly eroded market share . https://e-bookmarks.com/story7397759/copyright-s-flagship-product-and-big-pharma-a-risky-opportunity